ID Source | ID |
---|---|
PubMed CID | 5282759 |
CHEMBL ID | 1371781 |
CHEBI ID | 196194 |
SCHEMBL ID | 17266684 |
MeSH ID | M0322474 |
Synonym |
---|
EU-0100893 |
lopac-o-1008 |
NCGC00015764-01 |
LOPAC0_000893 |
LMFA01030074 |
c18:1n-8 |
cis-10-octadecenoic acid |
cis-10-oleic acid |
10z-octadecenoic acid |
NCGC00094211-01 |
NCGC00094211-02 |
NCGC00015764-02 |
O 1008 |
NCGC00015764-04 |
(z)-octadec-10-enoic acid |
CHEBI:196194 |
HMS3262D08 |
CCG-204975 |
NCGC00015764-03 |
LP00893 |
10-octadecenoic acid, (10z)- |
2442-70-8 |
NCGC00261578-01 |
tox21_500893 |
CHEMBL1371781 |
SCHEMBL17266684 |
SR-01000076043-1 |
sr-01000076043 |
SDCCGSBI-0050868.P002 |
NCGC00015764-05 |
STARBLD0005214 |
Class | Description |
---|---|
long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 35.4813 | 0.0032 | 45.4673 | 12,589.2998 | AID1705 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 28.3709 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 28.3709 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 15.8489 | 0.1259 | 19.1169 | 125.8920 | AID2353; AID2549 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID2323 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
endonuclease IV | Escherichia coli | Potency | 22.3872 | 0.7079 | 12.4324 | 31.6228 | AID1708 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 25.5536 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0126 | 10.6917 | 88.5700 | AID887 |
USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.3872 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 23.7781 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.7519 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.5406 | 17.6392 | 96.1227 | AID2364; AID2528 |
cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 39.8107 | 0.0025 | 5.8400 | 31.6228 | AID899 |
cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 39.8107 | 0.0063 | 6.9043 | 39.8107 | AID883 |
D(1A) dopamine receptor | Homo sapiens (human) | Potency | 2.5928 | 0.0224 | 5.9449 | 22.3872 | AID488982 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 50.1187 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
DNA polymerase beta | Homo sapiens (human) | Potency | 31.6228 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 12.5893 | 0.6561 | 9.4520 | 25.1189 | AID927 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 33.8078 | 0.4256 | 12.0591 | 28.1838 | AID504536 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 28.1838 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 31.6228 | 0.0046 | 11.3741 | 33.4983 | AID463097 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 37.6858 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 89.1251 | 0.1778 | 24.7352 | 79.4328 | AID488949 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 8.9125 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 6.3096 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 25.1189 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 36.5355 | 0.0063 | 8.2350 | 39.8107 | AID881; AID883 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.5893 | 1.5849 | 13.0043 | 25.1189 | AID927 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485368 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.69) | 29.6817 |
2010's | 6 (46.15) | 24.3611 |
2020's | 6 (46.15) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |